edoc

Clinical trials with anti-angiogenic agents in hematological malignancies

Medinger, Michael and Mross, Klaus. (2010) Clinical trials with anti-angiogenic agents in hematological malignancies. Journal of Angiogenesis Research, 2 (1). p. 10.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/43923/

Downloads: Statistics Overview

Abstract

New blood vessel formation (angiogenesis) is not only essential for the growth of solid tumors but there is also emerging evidence that progression of hematological malignancies like multiple myeloma, acute leukemias, and myeloproliferative neoplasms, also depends on new blood vessel formation. Anti-angiogenic strategies have become an important therapeutic modality for solid tumors. Several anti-angiogenic agents targeting angiogenesis-related pathways like monoclonal antibodies, receptor tyrosine kinase inhibitors, immunomodulatory drugs, and proteasome inhibitors have been entered clinical trials or have been already approved for the treatment of hematological malignancies as well and in some instances these pathways have emerged as promising therapeutic targets. This review summarizes recent advances in the basic understanding of the role of angiogenesis in hematological malignancies and clinical trials with novel therapeutic approaches targeting angiogenesis.
Faculties and Departments:03 Faculty of Medicine
UniBasel Contributors:Medinger, Michael
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:BioMed Central
e-ISSN:2040-2384
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:04 Oct 2017 09:31
Deposited On:04 Oct 2017 09:31

Repository Staff Only: item control page